BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37523811)

  • 21. Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma.
    Miller JA; Sahoo MK; Yamamoto F; Huang C; Wang H; Zehnder JL; Le QT; Pinsky BA
    Mol Cancer; 2022 Jul; 21(1):154. PubMed ID: 35902864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
    Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
    Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genotypic Characterization of Epstein Barr Virus in Blood of Patients with Suspected Nasopharyngeal Carcinoma in Ghana.
    Ayee R; Ofori MEO; Tagoe EA; Languon S; Searyoh K; Armooh L; Bilson-Amoah E; Baidoo K; Kitcher E; Wright E; Quaye O
    Viruses; 2020 Jul; 12(7):. PubMed ID: 32708700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnostics of nasopharyngeal carcinoma with Epstein-Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4) serological and molecular markers in cases of undetected primary tumor location.].
    Senyuta NB; Smirnova KV; Kondratova VN; Ignatova AV; Mudunov AM; Dushenkina TE; Liechtenstein AV; Gurtsevich VE
    Vopr Virusol; 2019; 64(5):229-237. PubMed ID: 32167688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
    Fung SY; Lam JW; Chan KC
    Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trans-oral brush biopsies and quantitative PCR for EBV DNA detection and screening of nasopharyngeal carcinoma.
    Ng RH; Ngan R; Wei WI; Gullane PJ; Phillips J
    Otolaryngol Head Neck Surg; 2014 Apr; 150(4):602-9. PubMed ID: 24486777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
    Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
    Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review.
    Xue F; He X
    Methods Mol Biol; 2020; 2204():99-107. PubMed ID: 32710318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Epstein-Barr Virus DNA Load and Serology as Screening Tools for Nasopharyngeal Carcinoma.
    Tay JK; Chan SH; Lim CM; Siow CH; Goh HL; Loh KS
    Otolaryngol Head Neck Surg; 2016 Aug; 155(2):274-80. PubMed ID: 27143706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epstein-Barr virus mir-bart1-5p detection via nasopharyngeal brush sampling is effective for diagnosing nasopharyngeal carcinoma.
    Zheng XH; Lu LX; Cui C; Chen MY; Li XZ; Jia WH
    Oncotarget; 2016 Jan; 7(4):4972-80. PubMed ID: 26701721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of nasal and nasopharyngeal swab collection for the detection of Epstein-Barr virus in nasopharyngeal carcinoma.
    Coghill AE; Wang CP; Verkuijilen SAWM; Yu KJ; Hsu WL; Middeldorp JM; Hildesheim A
    J Med Virol; 2018 Jan; 90(1):191-195. PubMed ID: 28833336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening.
    Chen Y; Zhao W; Lin L; Xiao X; Zhou X; Ming H; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
    PLoS One; 2015; 10(7):e0132669. PubMed ID: 26151639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma.
    Jiang C; Chen J; Xie S; Zhang L; Xiang Y; Lung M; Kam NW; Kwong DL; Cao S; Guan XY
    Int J Cancer; 2018 Dec; 143(12):3209-3217. PubMed ID: 29971780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA.
    Xue N; Lin JH; Xing S; Liu D; Li SB; Lai YZ; Wang XP; Mao MJ; Zhong Q; Zeng MS; Liu WL
    Cancer Res Treat; 2019 Jan; 51(1):378-390. PubMed ID: 29807404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.
    Dong H; Huang Z; Yang D; Li Z; Huang H; Meng Z; Qin Y; Kang M
    BMC Cancer; 2023 Jul; 23(1):673. PubMed ID: 37464319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical relevance of plasma EBV DNA as a biomarker for nasopharyngeal carcinoma in non-endemic areas: A multicenter study in southwestern China.
    He Q; Zhou Y; Zhou J; Zhao D; Li L; Li X; Huang Y; Wang Q; Zou H; Zhang K; Li Y; Wang Z; Deng Y; Meng F; Ying B; Yang M; Wang D
    Clin Chim Acta; 2023 Feb; 541():117244. PubMed ID: 36746264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of Epstein-Barr virus (EBV)-encoded microRNAs in plasma of patients with nasopharyngeal carcinoma.
    Gao W; Wong TS; Lv KX; Zhang MJ; Tsang RK; Chan JY
    Head Neck; 2019 Mar; 41(3):780-792. PubMed ID: 30548946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes.
    Nicholls JM; Lee VH; Chan SK; Tsang KC; Choi CW; Kwong DL; Lam KO; Chan SY; Tong CC; So TH; Leung TW; Luk MY; Khong PL; Lee AW
    Br J Cancer; 2019 Oct; 121(8):690-698. PubMed ID: 31527689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma.
    Liu W; Li H; Sheng H; Liu X; Chi P; Wang X; Mao M
    Adv Ther; 2020 Oct; 37(10):4280-4290. PubMed ID: 32780356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.